Skip to content

Study · Measured the body's own peptide · 2019

2 results

The endogenous oxytocin system in depressive disorders: A systematic review and meta-analysis.

Engel S, Laufer S, Knaevelsrud C, Schumacher S

Psychoneuroendocrinology11 Nov 2018Cited by 39 (Europe PMC)

PMID30458371 (opens in a new tab)DOI10.1016/j.psyneuen.2018.11.011 (opens in a new tab)PepBankPUB-30458371
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelSystematic reviewOther

    In a meta-analysis, basal endogenous oxytocin concentrations did not differ between patients with depressive disorders and healthy controls.

    In plain wordsPeople with depression and healthy people did not differ in the body's own basal oxytocin levels.

    Peptide
    Oxytocin
    Outcome
    No significant changeBasal endogenous oxytocin concentration, depressive disorders vs controls
    Study

    n = 546

    Comparator
    Healthy controls
    Outcome group
    Endogenous peptide levels · Mental health and mood

    Measurements

    Standardized mean difference (g)
    −0.02
    depressive patients vs healthy controls

    Source sentences

    Summary
    Standardized mean group differences were non-significant (g = -0.02, CI = [-0.41; 0.36]), indicating that depressive patients and healthy controls did not differ in basal endogenous oxytocin concentrations.
    1 context sentence
    Summary · context
    A systematic literature search was conducted to identify studies that measured basal endogenous oxytocin concentrations in depressive patients and healthy controls.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelSystematic reviewOther

    In studies with comparable risk of bias, the difference in basal endogenous oxytocin between patients with depressive disorders and controls was also non-significant.

    In plain wordsIn studies with comparable risk of bias, people with depression and healthy people also did not differ in the body's own oxytocin levels.

    Peptide
    Oxytocin
    Outcome
    No significant changeBasal oxytocin concentration, studies with comparable risk of bias
    Study

    n: not reported in source

    Comparator
    Healthy controls
    Outcome group
    Endogenous peptide levels · Mental health and mood

    Source sentences

    Summary
    Effects within studies showing comparable risks of biases, as rated according to the Newcastle-Ottawa Quality Assessment Scale, were non-significant as well, but homogeneous.
    1 context sentence
    Summary · context
    A systematic literature search was conducted to identify studies that measured basal endogenous oxytocin concentrations in depressive patients and healthy controls.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.